We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Omnia Biologics and AparnaBio Sign Lentivirus Drug Development Agreement
News

Omnia Biologics and AparnaBio Sign Lentivirus Drug Development Agreement

Omnia Biologics and AparnaBio Sign Lentivirus Drug Development Agreement
News

Omnia Biologics and AparnaBio Sign Lentivirus Drug Development Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Omnia Biologics and AparnaBio Sign Lentivirus Drug Development Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Omnia Biologics, Inc. and Aparna Biosciences Corp. have announced a deal for Omnia to provide AparnaBio with process development and production services. Omnia will provide lentiviral vector technical services as well as manufacture of research grade through cGMP grade materials.

“Despite recent setbacks in lentivirus based drug development on the business side, we continue to see great promise in the platform.” Dr. Dale VanderPutten, CEO, Omnia Biologics, Inc. commented on the deal. “The AparnaBio team has deep experience, a level of sophistication and a track record of success that gives them a leg up on successfully executing on the commercial potential of the lentivirus drug delivery concept. We are pleased to be chosen by AparnaBio as a partner in this development effort.”
Advertisement